

**New approaches aimed for the development of disease modifying therapies of Alzheimer's disease and other dementia diseases**

Chairs : Takeshi Iwatsubo

The University of Tokyo, Neuropathology

Kenjiro Ono

Division of Neurology, Department of Medicine, Showa University School of Medicine

**NFS-01-1 The pathological link of glia activation with amyloid clearance in Alzheimer disease**

Taisuke Tomita

Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan

**NFS-01-2 Principles of Inflammasome Priming and Inhibition: Implications for Neurodegenerative Disorders**

Giulio M. Pasinetti

Icahn School of Medicine at Mount Sinai, USA / James J Peters Veterans Affairs Medical Center, USA

**NFS-01-3 HMW A $\beta$  oligomers are important targets for disease modifying approach of Alzheimer's disease**

Kenjiro Ono

Division of Neurology, Department of Medicine, School of Medicine, Showa University, Japan

**NFS-01-4 canceled**

**Original discovery and therapy for SCA from Japan to the world**

Chairs : Yoshitaka Nagai

Department of Neurotherapeutics, Osaka University Graduate School of  
Medicine

Kinya Ishikawa

The Center for Personalized Medicine for Healthy Aging, Tokyo Medical and  
Dental University

**NFS-02-1 Pathogenesis of spinocerebellar ataxia type 31 (SCA31)**

Kinya Ishikawa

The Center for Personalized Medicine for Healthy Aging, Tokyo Medical and Dental  
University, Japan

**NFS-02-2 Current clinical characteristics of Asidan (SCA36)**

Yasuyuki Ohta

Department of Neurology, Okayama University, Japan

**NFS-02-3 Development of disease-modifying therapy for polyglutamine-linked SCA**

Yoshitaka Nagai

Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Japan

**NFS-02-4 Antisense oligonucleotide therapy in spinocerebellar ataxia type 3 (SCA3)/Machado-Joseph disease**

Henry L. Paulson

University of Michigan, USA

**NFS-03 Neuroscience Frontier Symposium 03****En**

Sep 2 (Wed) 13 : 45 ~ 15 : 15 Room 03 "Main Hall" (Okayama Convention Center 3F Convention Hall)

**Leading edge of ALS research**

Chairs : Clotilde Lagier-Tourenne  
 Massachusetts General Hospital / Harvard Medical School  
 Masahisa Katsuno  
 Department of Neurology, Nagoya University

**NFS-03-1** Antibody-based Therapeutic strategies for ALS targeting misfolded proteins

**Makoto Urushitani**  
 Department of Neurology, Shiga University of Medical Science, Japan

**NFS-03-2** Disruption of RNA metabolism in neurodegenerative diseases and emerging therapeutic strategies

**Clotilde Lagier-Tourenne**  
 Sean M. Healey & AMG Center for ALS at the Massachusetts General Hospital, USA / Harvard Medical School, USA

**NFS-03-3** Glia-immune communication in ALS

**Koji Yamanaka**  
 Department of Neuroscience and Pathobiology, RIEM, Nagoya University, Japan

**NFS-03-4** TDP-43 facilitates exocytosis: unexpected link between ALS and diabetes

**Masahisa Katsuno**  
 Department of Neurology, Nagoya University Graduate School of Medicine, Japan